Alere Continues Executing And Building Credibility
Alpha Gen Capital
Alpha Gen Capital
Alere Executing On Its Transition To A Focused Portfolio Of Assets
Alpha Gen Capital
Alpha Gen Capital
Fri, Oct. 21, 5:36 PM
Fri, Oct. 21, 10:48 AM
- Unsurprisingly, Alere (ALR +0.7%) stockholders voted overwhelmingly in favor of a merger with Abbott (ABT -1.1%) in a special meeting. Over 98% of the votes cast (representing 77% of the company's outstanding shares) backed the $56/share transaction. Yesterday's close was $44.10.
- The companies announced the deal in January but it became a bit wobbly when a rash of problems arose at Alere including dodgy billing practices, inappropriate revenue recognition and a government inquiry into its marketing and billing practices. The firms have agreed to engage a mediator to settle their differences.
- Read now: Merger Arbitrage - Alere And Abbott
Tue, Oct. 11, 12:35 PM
- In a statement, the FDA reports that it has concluded that Johnson & Johnson's (JNJ -1.6%) blood thinner XARELTO (rivaroxaban) is a safe and effective alternative to warfarin in patients with atrial fibrillation. The agency conducted a variety of analyses on a Phase 3 study, ROCKET-AF, that supported the company's marketing application and 2011 approval.
- The FDA reexamined the data because Alere's (ALR -1.6%) INRatio device was used to monitor warfarin therapy in the control group. Alere recalled the device in July of this year due to the risk of inaccurate results.
Thu, Sep. 8, 1:07 PM
- Alere (ALR +0.2%) and cold-footed Abbott Laboratories (ABT -0.2%) have agreed to work with a mediator to settle their disagreements over Abbott's now-rocky $5.8B bid for the point-of-care diagnostics firm. According to court filings, the companies are considering former Delaware Chancellor William Chandler for the job. Alere recently filed a lawsuit in Delaware to force Abbott to follow through on its offer.
- Abbott appears to have lost enthusiasm for the deal at its current valuation, influenced, no doubt, by a rash of problems at Alere including restating financials due to inappropriate revenue recognition and a government inquiry into its billing and marketing practices.
- Alere has accused Abbott of cooling to the deal because of its $25B St. Jude Medical takeover. Abbott counters by saying the delay in closing the transaction is due to Alere's failure to file its regulatory submissions on time.
- Read now Merger Arbitrage - Alere and Abbott
Tue, Sep. 6, 7:42 AM
Tue, Sep. 6, 7:08 AM
Fri, Aug. 26, 11:47 AM
- Abbott's (ABT +0.4%) wobbly deal to acquire point-of-care diagnostics outfit Alere (ALR -1.9%) just got nastier. Yesterday, the Waltham, MA-based firm filed a complaint in Delaware Chancery Court aiming to force Abbott to go through with its $56/share offer ($5.8B) announced earlier this year. Abbott is trying to back out of the transaction because it has lost confidence in the robustness of Alere's internal controls. In April, Abbott reportedly offered Alere $50M to call it off, an offer it rejected.
- Five months after Abbott announced the intended takeover, Alere disclosed that it would need to restate its annual financial statements for the years 2013, 2014 and 2015, in addition to two interim reports for 2015, due to revenue recognition issues in certain ex-U.S. markets. It also stated that it expected to report one or more material weaknesses in its disclosure controls and procedures and its internal control over financial reporting.
- A short time later, the news broke that Alere was being investigated by the U.S. Department of Justice over its government billing practices in its toxicology unit, specifically the offering of inducements to doctors to order its tests. The Feds regard these activities as illegal kickbacks.
- Previously: Alere almost there with 2015 10-K filing; analysts say Abbott deal on track; ALR shares up 8% (July 15)
- Previously: Alere in Feds' crosshairs over billing practices as woes mount; Abbott deal on the rocks; shares slump 30% at close (July 27)
Fri, Aug. 19, 7:53 AM
- Alere (NYSE:ALR) receives 501(k) clearance for its Alere i RSV test, a rapid point-of-care molecular diagnostic assay that can detect RSV in no more than 13 minutes. The product is the third approved test in its i platform (Strep A and Influenza A&B).
- The company intends to apply for a CLIA waiver shortly which will allow non-laboratory technology-trained personnel to perform the test. The FDA extends the designations to labs that perform simple assays that present little risk of error.
Wed, Aug. 17, 6:49 AM
Wed, Aug. 17, 6:26 AM
Fri, Aug. 12, 8:04 AM
- TeamHealth Holdings (NYSE:TMH) upgraded to Buy from Hold with a $52 (41% upside) price target by Jefferies.
- Editas Medicine (NASDAQ:EDIT) upgraded to Buy from Hold with a $35 (69% upside) price target by Jefferies.
- ZIOPHARM Oncology (NASDAQ:ZIOP) upgraded to Market Perform from Underperform by Wells Fargo. Target price range: $5 - 8 (25% upside from midpoint).
- Bellicum Pharmaceuticals (NASDAQ:BLCM) upgraded to Buy from Neutral with a $24 (22% upside) price target by Citigroup.
- Alere (NYSE:ALR) upgraded to Buy from Neutral with a $48 (20% upside) price target by BTIG Research.
- Merck (NYSE:MRK) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $73 (15% upside) from $62. Upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $72 (13% upside) from $62.
- Celgene (NASDAQ:CELG) upgraded to Buy from Neutral with a $138 (21% upside) price target by BTIG Research.
- Bristol-Myers Squibb (NYSE:BMY) downgraded to Hold from Buy by Berenberg. Price target lowered to $70 (15% upside) from $80. Downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $63 (3% upside) from $86.
- Zosano Pharma (NASDAQ:ZSAN) downgraded to Neutral from Buy by Ladenburg Thalmann.
- Myriad Genetics (NASDAQ:MYGN) downgraded to Hold from Buy by Gabelli & Co. Price target lowered to $32 (54% upside) from $46.
- Ohr Pharmaceutical (NASDAQ:OHRP) downgraded to Hold from Buy by Brean Capital.
- Inovio Pharmaceuticals (NASDAQ:INO) downgraded to Hold from Buy by Maxim Group. $14 price target removed.
- Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Neutral from Buy by Citigroup. Price target raised to $8 (19% upside) from $6.
- Regeneron Pharmaceuticals (NASDAQ:REGN) downgraded to Neutral from Outperform by Baird. Price target lowered to $488 (16% upside) from $505.
Mon, Aug. 8, 10:32 AM| Mon, Aug. 8, 10:32 AM | 14 Comments
Mon, Aug. 8, 9:24 AM
Mon, Aug. 8, 6:29 AM
Thu, Jul. 28, 12:59 PM
Thu, Jul. 28, 11:00 AM